Truxima, Reinadoamine and acalabrutinib treatment for relapsed invasive invasive B-cell lymphoma: safe and effective
-
Last Update: 2020-06-25
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Data from the 25th EHA Virtual Conference showed that Truxima ® (biosimilar rituximab) combined with the nadoamine and acalabrutinib (R2A) protocol to treat recurrent refractory invasive B cellslymphomawith good tolerance and effectivenessThe purpose of this Phase II clinical trial is to assess the safety and efficacy of R2A treatment of regenerative invasive B-cell lymphomatreated a total of 22 patients between the first entry in July 2019 and the February 2020 data cut-off, with a median follow-up time of 3.2 monthsMost patients (73%) have diffuse large B-cell lymphoma (DLBCL)The primary endpoints of the study were the Overall Mitigation Rate (ORR), which included total mitigation rate (CR), progression-free survival (PFS), overall lifetime (OS), and security profilesIn 13 patients who were evaluated for disease after the R2A protocol, an objective response was observed in 69% of patients and CR was observed in 31% of patientsThe 6-month PFS rate was 83%, and only one patient developed disease progression after the initial objective response
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
